Dopaminergic agonists normalize elevated hypothalamic neuropeptide Y and corticotropin-releasing hormone, body weight gain, and hyperglycemia in ob/ob mice.
about
Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese ratCharacterization and mapping of bovine dopamine receptors 1 and 5.A randomized, double-blind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes therapy and either Cycloset or placebo.Intranasal cabergoline: pharmacokinetic and pharmacodynamic studies.Enhanced hypothalamic leptin signaling in mice lacking dopamine D2 receptors.Brain-derived neurotrophic factor regulates hedonic feeding by acting on the mesolimbic dopamine systemEnergy regulatory signals and food reward.Bromocriptine increased operant responding for high fat food but decreased chow intake in both obesity-prone and resistant rats.The role of dopamine in motivation for food in humans: implications for obesity.Imaging of brain dopamine pathways: implications for understanding obesity.Bromocriptine mesylate: Food and Drug Administration approved new approach in therapy of non-insulin dependant diabetes mellitus with poor glycemic controlHypothalamic neuropeptide Y (NPY) and the attenuation of hyperphagia in streptozotocin diabetic rats treated with dopamine D1/D2 agonists.Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR ratsImpact of Bromocriptine-QR Therapy on Glycemic Control and Daily Insulin Requirement in Type 2 Diabetes Mellitus Subjects Whose Dysglycemia Is Poorly Controlled on High-Dose Insulin: A Pilot Study.Weighing in the role of BDNF in the central control of eating behavior.Nicotinic α4 Receptor-Mediated Cholinergic Influences on Food Intake and Activity Patterns in Hypothalamic Circuits.Randomized pilot study of cabergoline, a dopamine receptor agonist: effects on body weight and glucose tolerance in obese adultsCrosstalk between metabolic and neuropsychiatric disordersHypothalamic overexpression of mutant huntingtin causes dysregulation of brown adipose tissue.Food reinforcement and eating: a multilevel analysis.Exposure to elevated levels of dietary fat attenuates psychostimulant reward and mesolimbic dopamine turnover in the rat.Insulin, leptin, and food reward: update 2008.PET measurement of changes in D2/D3 dopamine receptor binding in a nonhuman primate during chronic deep brain stimulation of the bed nucleus of the stria terminalis.Bromocriptine administration reduces hyperphagia and adiposity and differentially affects dopamine D2 receptor and transporter binding in leptin-receptor-deficient Zucker rats and rats with diet-induced obesityEvidence for defective mesolimbic dopamine exocytosis in obesity-prone rats.Relation of obesity to consummatory and anticipatory food reward.Effects of cabergoline on blood glucose levels in type 2 diabetic patients: A double-blind controlled clinical trial.Brain signaling systems in the Type 2 diabetes and metabolic syndrome: promising target to treat and prevent these diseases.Role of prenatal undernutrition in the expression of serotonin, dopamine and leptin receptors in adult mice: implications of food intake.Mood disorders and obesity: understanding inflammation as a pathophysiological nexus.Pharmacogenetic testing to predict antipsychotic-induced weight gain: a systematic review.Hypothalamic adrenergic receptor changes in the metabolic syndrome of genetically obese (ob/ob) mice.Blockade of the leptin-sensitive pathway markedly reduces alcohol consumption in mice.Effect of bromocriptine-QR therapy on glycemic control in subjects with type 2 diabetes mellitus whose dysglycemia is inadequately controlled on insulin.Impact of bromocriptine-QR therapy on cardiovascular outcomes in type 2 diabetes mellitus subjects on metformin.Impact of Adiposity and Fat Distribution on the Dynamics of Adrenocorticotropin and Cortisol Rhythms.Evidence-based practice use of quick-release bromocriptine across the natural history of type 2 diabetes mellitus.Metabolic and Cardiovascular Benefits and Risks of EMD386088-A 5-HT6 Receptor Partial Agonist and Dopamine Transporter Inhibitor.Differential involvement of dopamine D1 and D2 receptors and inhibition by dopamine of hypothalamic VMN neurons in early postnatally overfed juvenile rats.Expression of dopaminergic receptors in the hypothalamus of lean and obese Zucker rats and food intake.
P2860
Q24602893-52C3D5E7-B63E-4AD3-BAE4-F1AB6001CAB2Q30966859-D2C73B3B-2378-42BA-AC76-D22EC3122A69Q33288874-6572A447-FD5F-4FA1-AFF6-BD073DC5AB08Q33563553-A38AFAF2-D7C0-498D-87F9-5A0A5506C8E8Q33726520-62BAB97D-EFD6-4A03-ABA2-9E02BBEDD39EQ33758309-DC515311-0380-4D6A-AC4B-C0BA5DC9B48CQ33965245-CC159106-ADB0-4C09-922D-7349E34642E3Q34476706-D1731825-CE00-415C-9C05-5610B5CEED2CQ34974781-D387F871-00DE-4C7A-A283-3A793FA0D7F7Q34995403-6C8320B4-589F-4AB0-884A-6CEBC0021283Q35138031-4AF657FD-5AD0-49A5-91E3-36F5128C9BAAQ35546211-5380BAB9-10D4-4557-AD49-87B6EFD107C0Q35559692-6EC0E2DE-9822-4491-8B32-439AA4AF080AQ35594627-D3219426-6F02-4DAB-84E4-66179625182CQ35607668-13C1B85E-4785-40E5-A35C-2DE641AEC8A6Q35738540-3E95F200-4DC0-4C91-9A0E-ACE3B571D339Q35791125-E76C6E18-7FCB-4440-8C42-0211C7674C5BQ36073458-4825726A-EF05-4868-8DBE-9D30EE8DF306Q36106687-69C26A9D-1477-47D5-9C04-3106A80E1A74Q36416603-3F7AEBA3-CFB2-4E98-A535-A1A975947D54Q37002427-9A952B48-77C7-461D-BB65-D75768354EF0Q37086372-F6FFB683-1AC6-4B8C-822E-E5D7DF2CDC3EQ37089254-6F9A40BF-D1C4-468C-AA81-A21870149D13Q37189415-E0BA3282-E150-4C4F-93B3-8FFA169301EDQ37309456-F2FD4396-8435-44BC-A7DC-25794E2116E6Q37325056-C3F55D17-C6D7-4AB2-8E37-62F233739A22Q37328780-E98CC921-B28E-4968-9A1F-2F23BD504558Q37474214-3C4849CB-2352-4C87-865C-69BCD420CBE8Q37496349-5E7CD19A-1461-46FF-93CA-491C1AAFB761Q37821806-2C837AE9-CB8D-43C8-A0A3-7C96F2E6D518Q37917782-C46D2019-1FEA-4C4F-8C31-815B605AFF56Q38309530-4B7971F2-7ECA-43BB-9214-C6D729A35D3FQ38334207-A7A081BB-5555-432D-BC7E-65D0574872AFQ38378534-9A0D4F33-A968-4C1E-89F6-42A8015B64FAQ38386992-69B834B9-0FBB-4E17-BE95-06276B89EDBEQ38655627-FC3061B2-184A-46F1-8BAB-9F5DB3C93FB9Q38908684-BEA9C41A-56CB-4096-BF5C-476D31CA08BDQ42323374-6E04AC51-B029-4BA5-8902-AEA8993AD594Q43944433-29CE050C-BE44-4EF5-A4FB-5ABEB19150E6Q44135024-C71A60FD-2A8E-48B0-9979-50E8DC537F8D
P2860
Dopaminergic agonists normalize elevated hypothalamic neuropeptide Y and corticotropin-releasing hormone, body weight gain, and hyperglycemia in ob/ob mice.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Dopaminergic agonists normaliz ...... d hyperglycemia in ob/ob mice.
@en
type
label
Dopaminergic agonists normaliz ...... d hyperglycemia in ob/ob mice.
@en
prefLabel
Dopaminergic agonists normaliz ...... d hyperglycemia in ob/ob mice.
@en
P921
P356
P1433
P1476
Dopaminergic agonists normaliz ...... d hyperglycemia in ob/ob mice.
@en
P2093
P356
10.1159/000054522
P577
2000-01-01T00:00:00Z